Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
In 2023, the FDA banned compounding pharmacies from producing specific peptides because they were identified as posing "potential significant safety risks" by the agency
Is AOD-9604 safe
Trade-offs include less flexibility in dose adjustment and prolonged exposure if adverse effects develop
BPC-157 + TB-500 Combination Research Use Only High-purity BPC-157 and TB-500 supplied together exclusively for laboratory and research applications
If you are pregnant, nursing, taking medication, or have a medical condition, consult your health care professional before using products based on this content
Gastrointestinal effects: the main titration bottleneck Nausea, diarrhea, constipation, and vomiting run around 40 to 44% overall, dose-dependent in how many people report them but mild-dominant in severity: severe events stay at or below about 1.7% in any category even at the top dose. In the obesity program the by-dose rates run nausea 25/29/28%, diarrhea 19/21/23%, and vomiting 8/11/13% at 5/10/15 mg. They concentrate during escalation and ease with time on a held dose
